Nonepileptic myoclonus is a common feature in Angelman adolescents and young adults, and although it…
Ana Pena, PhD
Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
The U.S. Food and Drug Administration (FDA) has designated  NSI-189 an orphan drug to help…
Ganaxolone reduced seizures, anxiety and improved motor deficits in a mouse model of…
Loss of the protein that contributes to Angelman syndrome led to a decrease in the ability of vision-related nerve…
Specific differences in the gait of children with Angelman syndrome may be used as a tool for disease…
The protocol used by Australian researchers to create the Global Angelman Syndrome Registry, the first worldwide patient…
Anxiety and movement disorders may increase with age in adults with Angelman syndrome, while the prevalence of seizures…
Taurine was able to recover motor capacity, learning and memory skills in a mouse model of Angelman syndrome,…
Early and careful detection of the spectrum of neurodevelopmental disabilities in children with Angelman syndrome is essential to…
The loss of a fundamental protein in the brain may explain how genetic changes in Angelman syndrome lead…